








A**B****C****E****F****D****G**

Supplemental Figure S6. Nuclear ARRB1 levels correlate with cell sensitivity to pharmacological HIF1A inhibition

A. Relative *SDHA* (left) and *FH* (right) mRNA levels in nucARRB1 transiently transfected with empty vector control (ev), *SDHA*, *FH* or equal amounts of *SDHA* and *FH* expression vectors. GFP control cells transfected with ev were used as a control and baseline for HIF1A expression levels.

B. Quantification of the HIF1A protein levels in the blot showed in A. Expression of *FH* or *SDHA* in nucARRB1 cells lowers HIF1A expression levels to levels similar to that seen in GFP with ev control. Combined expression of *FH* and *SDHA* in nucARRB1 result in a 40% reduction in the levels of HIF1A (compared to nucARRB1+ev) and a 30% reduction compared to GFP+ev control.

C. HIF1A protein levels were assessed by immunoblotting in a panel of prostate cancer cell lines under normoxic and hypoxic (1% O₂ for 8hrs) conditions.

D. Quantification of the HIF1A and ARRB1 (total, nuclear or cytoplasmic) protein levels in a panel of prostate cancer cells. The blot in C was used to quantify HIF1A levels and the blot on Figure 2A was used to quantify the levels of ARRB1 in the same cell lines. Nuclear ARRB1 levels correlate with the levels of HIF1A i.e. lines with low nuclear ARRB1 also display the lowest levels of HIF1A. Cytoplasmic levels of ARRB1 do not show any correlation with HIF1A levels.

E. HIF1A, *FH* and *SDHA* protein expression levels were determined by immunoblotting in low (LNCaP) and high (C4-2) ARRB1-expressing cell extracts.

F. LNCaPs and C4-2 were treated with PHD activators me2OG (2.5mM) and R59949 (30uM) and HIF1A protein levels were determined by immunoblot after 2 days.

G. LNCaP and C4-2 cell numbers 3 days post-treatment with me2OG or R59949.